Table 5.

Combination of anti-H. pylori seropositivity and pepsinogen I on risk of noncardia gastric cancer by Lauren classification in ATBC Study

	control (n=3,291)		case (n=197)		model 1		model 2
	N	%	N	%	OR	95% CI	OR	95% CI
Intestinal Type Gastric Cancer (n=69)
Group A	736	22.4	5	7.3	ref		ref
Group B	2,257	68.6	51	73.9	3.47	1.37–8.73	4.23	1.52–11.80
Group C	279	8.5	12	17.4	7.02	2.42–20.39	8.65	2.72–27.50
Group D	19	0.6	1	1.5	8.86	0.98–80.45	11.95	1.25–114.23
p-trend					<0.0001		<0.0001
Diffuse Type Gastric Cancer (n=49)
Group A	736	22.4	5	10.2	ref		ref
Group B	2,257	68.6	40	81.6	2.69	1.05–6.86	2.57	1.00–6.59
Group C	279	8.5	4	8.2	2.27	0.60–8.64	1.74	0.41–7.46
Group D	19	0.6	0	0.0	-		-
p-trend					0.15		0.25
Other Type Gastric Cancer (n=79)
Group A	736	22.4	4	5.1	ref		ref
Group B	2,257	68.6	52	65.8	4.53	1.63–12.58	4.25	1.52–11.84
Group C	279	8.5	19	24.1	14.69	4.90–44.01	13.92	4.61–42.09
Group D	19	0.6	4	5.1	46.21	10.60–201.47	43.81	9.89–194.11
p-trend					<0.0001		<0.0001

Abbreviations: ATBC - Alpha-Tocopherol, Beta-Carotene Cancer Prevention, OR – odds ratio, CI – confidence interval, SPGI- Serum pepsinogen I

Group A: H. pylori (−) and normal SPGI, Group B: H. pylori (+) and normal SPGI, Group C: H. pylori (+) and low SPGI, Group D: H. pylori (−) and low SPGI

model 1: adjusted for age at randomization and type of intervention

model 2: model 1 + body mass index, pack years of smoking, alcohol drinking, education, fruit intake, vegetable intake